Navigation Links
Study Finds Letter to Health Care Providers Results in Reduction of Potentially Unsafe Concurrent Use of Plavix and Proton Pump Inhibitors
Date:4/18/2011

ST. PAUL, Minn., April 18, 2011 /PRNewswire/ -- A letter sent by a commercial insurer to health care providers notifying them of potentially unsafe drug use when combining anti-clotting drug clopidogrel (Plavix®) with a proton pump inhibitor (PPI), showed a significant reduction in the number of members combining the drugs, according to a new study by pharmacy benefit management thought leader Prime Therapeutics (Prime). Details of the study will be presented on April 29th at the Academy of Managed Care Pharmacy's 23rd Annual Meeting in Minneapolis, Minn.

Recent data has shown the use of some PPIs, commonly prescribed to reduce gastric acid production, in combination with clopidogrel, an antiplatelet medication used to prevent stroke and heart attack, can increase a person's risk for clopidogrel failure and a subsequent cardiac event. Current guidelines suggest providers re-evaluate the need for PPI therapy in patients taking clopidogrel and consider recommending another type of heartburn medication as an alternative treatment.

Researchers from Prime and one of its Blue Cross and Blue Shield clients used a retrospective drug utilization review to analyze claims data from a 1.3 million member commercial insurer. From this, researchers determined 1,316 members were actively combining clopidogrel with a PPI. A letter was then sent to health care providers alerting them of the potentially unsafe drug use and requesting the provider re-evaluate the need for PPI therapy in their patients. The study also tracked a control group of 2,740 patients who met intervention criteria but whose providers did not receive a letter.

At 180 days post-letter, actively enrolled members in both groups were assessed for the presence of a PPI, clopidogrel, or both. This analysis showed a significant absolute 7.5 percentage point reduction in the number of members who were combining PPIs and clopidogrel when they received the letter, compared to the control group.
'/>"/>

SOURCE Prime Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
6. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
7. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
8. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
9. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
10. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
11. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Dec. 23, 2014 Echo Therapeutics, Inc. ... company focused on skin permeation, continuous glucose monitoring ... W. Hollander has been appointed Chief Executive ... more than 20 years of experience in the ... most recently served as Vice President, Business Development, ...
(Date:12/24/2014)... , Dec. 23, 2014 ResMed (NYSE: ... patent infringement action against Chinese medical device manufacturer BMC Medical ... ruled today that BMC,s masks listed below infringe ResMed,s patents, ... selling these masks in the United States ... N2 nasal mask , Willow nasal pillows mask ...
(Date:12/24/2014)... 23, 2014   Synageva BioPharma Corp. ... developing therapeutic products for rare disorders, today announced ... the Marketing Authorization Application (MAA) for sebelipase alfa ... company,s request for accelerated assessment, which has the ... The MAA, and the Biologics ...
Breaking Medicine Technology:Echo Therapeutics Announces Scott W. Hollander as President & Chief Executive Officer 2Echo Therapeutics Announces Scott W. Hollander as President & Chief Executive Officer 3ResMed Wins Patent Infringement Lawsuit Against Chinese Manufacturer BMC Medical 2Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 2Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 3
... AMRI (NASDAQ: AMRI ), a leading ... appointment of Ian Shott as President of AMRI Europe, ... In this newly created role, Mr. Shott will have ... company,s site in Wales, United Kingdom, and work closely ...
... SALT LAKE CITY, May 22, 2012   USANA Health ... global nutritional supplement company, today announced the promotion of ... and development and Dr. Brian Dixon to executive director ... Steely, a licensed naturopathic physician, Mark Levy, a Ph.D. ...
Cached Medicine Technology:AMRI Announces President for AMRI Europe 2AMRI Announces President for AMRI Europe 3USANA Health Sciences Expands Award-Winning Research and Development Team 2USANA Health Sciences Expands Award-Winning Research and Development Team 3
(Date:12/26/2014)... 2014 DW-InductionHeating.com (DaWei Induction Heating Co.) ... and developing, producing and marketing of a series of ... announces their new series of induction brazing equipments ... company, induction brazing refers to the joining ... material and heat. The manager says that there are ...
(Date:12/25/2014)... 26, 2014 The report “Nintedanib ... 2023” focuses on the current treatment landscape, unmet ... colorectal cancer market. Stivarga is a drug which ... rectal cancer. Boehringer Ingelheim is developing nintedanib (BIBF-1120), ... of refractory CRC in the US, Europe, and ...
(Date:12/25/2014)... Recently, Dylan Queen, a famous online company supplying women’s ... discounted prom dresses, most of which are priced under ... company, the promotion is valid until Jan. 22, 2015; ... UK market. , The prom dresses in this new ... A-line strapless, empire strapless chiffon, one shoulder, floor-length, V-neck ...
(Date:12/25/2014)... (PRWEB) December 25, 2014 When head lice ... themselves in a frenzy to get rid of it while ... families in Coral Gables now have the solution right in ... salon clinic location, Lice Troopers provides full spectrum head lice ... Coral Gable area, including Sunset, Key Biscayne, Brickell, Coconut Grove, ...
(Date:12/25/2014)... 2014 (HealthDay News) -- Among early stage breast cancer ... half of one percent will eventually develop leukemia as ... The finding comes from a review of more ... 2007, and it suggests that the risk for developing ... had previously thought. "The frequency of bone marrow ...
Breaking Medicine News(10 mins):Health News:Induction Brazing Equipment Series From DaWei Induction Heating Co., A Reliable Supplier Of Induction Heating Equipment 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 4Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2Health News:Coral Gables Florida Gets Ready to Be Lice-Free with Lice Troopers 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 3
... it has received approval from the U.S. Food and ... gum USP, 2 mg (coated fruit) and 4 mg ... marketed under store brand labels and is comparable to ... aid to smoking cessation. "This first store brand approval ...
... the advent of a possible new blockbuster drug and ... and drug addictions, global sales of smoking cessation and ... of little over $1.1 billion in 2005 to more ... and Addiction Treatments: A World Market Analysis, a new ...
... of mobile phones in the provision of clinical care are ... and Safety in Health Care argues. ,Healthcare ... to help improve the provision of care to people with ... disease. ,The UK and the US are leading ...
... Medarex, Inc. today announced a collaborative research agreement ... Chemical Holdings Corporation . The two companies expect ... against a Mitsubishi target for the potential treatment ... Medarex's UltiMAb Human Antibody Development System(R) to generate ...
... the most common addiction all over the world, and a ... impact of tobacco in its various forms on human health, ... smoking. ,Tobacco generates about Rs.7,964 crore ... about Rs.27,661 crore, according to WHO estimates. ...
... risk the wrath of the country's 350 million smokers today by ... ,"It will be applied in all Olympic venues and ... ,A sign of the passions the issue can raise ... ,Earlier this month, an attempt by security guards ...
Cached Medicine News:Health News:Perrigo Receives FDA Approval to Market Coated Fruit Nicotine Gum 2Health News:Urgent Need for Guidance on Mobile Phone Use in Clinical Care 2Health News:Tobacco Menace and What can Be Done About It 2Health News:Tobacco Menace and What can Be Done About It 3Health News:Tobacco Menace and What can Be Done About It 4Health News:China Bans Smoking at Olympics 2